ביודרוקסיל 250 מג5 מל
masrouji co, ltd - cefadroxil as monohydrate - תרחיף - cefadroxil as monohydrate 250 mg / 5 ml
ביודרוקסיל 500 מג
masrouji co, ltd - cefadroxil as monohydrate - קפסולות - cefadroxil as monohydrate 500 mg - cefadroxil
זינט טבליות 500 מג
novartis israel ltd., israel - cefuroxime as axetil - טבליה - cefuroxime as axetil 500 mg - cefuroxime
ארלזי 25
novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 25 mg / 0.5 ml - etanercept
ארלזי 50
novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg / 1 ml - etanercept
ריקסתון
novartis israel ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg / 1 ml - rituximab
היירימוז
novartis israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab
פולבסטרנט סנדוז
novartis israel ltd - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant
טייקרב
novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.
קווטיאפין סנדוז 150 מג פי. אר.טי
novartis israel ltd - quetiapine as fumarate - טבליות בשחרור ממושך - quetiapine as fumarate 150 mg - quetiapine